Now with actual data in hand, Celgene touts an early response for Crohn’s drug mongersen
A month after posting an underwhelming top-line assessment of a Phase Ib study of its closely watched Crohn’s drug mongersen (GED-0301) for Crohn’s disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.